Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 7498151, 14 pages
https://doi.org/10.1155/2017/7498151
Research Article

Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma

1Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
2Department of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China

Correspondence should be addressed to Jie Chen; moc.361@003199eijnehc and Yumin Wang; moc.361@7750myw

Received 31 May 2017; Revised 24 August 2017; Accepted 13 September 2017; Published 27 November 2017

Academic Editor: Paul Harrison

Copyright © 2017 Lijuan Hu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J.-P. Pignon, H. Tribodet, G. V. Scagliotti et al., “Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group,” Journal of Clinical Oncology, vol. 26, no. 21, pp. 3552–3559, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Zarogoulidis, P. Zarogoulidis, K. Darwiche et al., “Treatment of non-small cell lung cancer (NSCLC),” Journal of Thoracic Disease, vol. 5, Suppl 4, pp. S389–S396, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. P. A. Bunn and K. Kelly, “New combinations in the treatment of lung cancer: a time for optimism,” Chest, vol. 117, no. 4, pp. 138S–143S, 2000. View at Publisher · View at Google Scholar
  4. S. C. Spiro and G. A. Silvestri, “One hundred years of lung cancer,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 5, pp. 523–529, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. M.-K. Choi and D.-D. Kim, “Platinum transporters and drug resistance,” Archives of Pharmacal Research, vol. 29, no. 12, pp. 1067–1073, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. L. P. Martin, T. C. Hamilton, and R. J. Schilder, “Platinum resistance: the role of DNA repair pathways,” Clinical Cancer Research, vol. 14, no. 5, pp. 1291–1295, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Wangpaichitr, C. Wu, M. You et al., “Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins,” European Journal of Pharmacology, vol. 591, no. 1-3, pp. 124–127, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Sève and C. Dumontet, “Chemoresistance in non-small cell lung cancer,” Current Medicinal Chemistry - Anti-Cancer Agents, vol. 5, no. 1, pp. 73–88, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Ohmichi, J. Hayakawa, K. Tasaka, H. Kurachi, and Y. Murata, “Mechanisms of platinum drug resistance,” Trends in Pharmacological Sciences, vol. 26, no. 3, pp. 113–116, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Wu, M. Wangpaichitr, L. Feun et al., “Overcoming cisplatin resistance by mTOR inhibitor in lung cancer,” Molecular Cancer, vol. 4, no. 1, p. 25, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Zhou, Z. Zhang, H. Zhao, S. Bao, L. Cheng, and J. Sun, “An immune-related six-lncrna signature to improve prognosis prediction of glioblastoma multiforme,” Molecular Neurobiology, pp. 1–14, 2017. View at Publisher · View at Google Scholar
  12. M. Zhou, Z. Diao, X. Yue et al., “Construction and analysis of dysregulated lncRNA-associated ceRNA network identified novel lncRNA biomarkers for early diagnosis of human pancreatic cancer,” Oncotarget , vol. 7, no. 35, pp. 56383–56394, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Zhou, H. Zhao, W. Xu, S. Bao, L. Cheng, and J. Sun, “Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma,” Molecular Cancer, vol. 16, no. 1, article no. 16, 2017. View at Publisher · View at Google Scholar · View at Scopus
  14. W. Guo, Q. Wang, Y. Zhan et al., “Transcriptome sequencing uncovers a three-long noncoding RNA signature in predicting breast cancer survival,” Scientific Reports, vol. 6, Article ID 27931, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Zhou, Y. Sun, Y. Sun et al., “Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer,” Oncotarget , vol. 7, no. 22, pp. 32433–32448, 2016. View at Publisher · View at Google Scholar
  16. Z. Tu, D. He, X. Deng et al., “An eight-long non-coding RNA signature as a candidate prognostic biomarker for lung cancer,” Oncology Reports, vol. 36, no. 1, pp. 215–222, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Zhou, X. Wang, H. Shi et al., “Characterization of long non-coding RNA-associated ceRNA network to reveal potential prognostic lncRNA biomarkers in human ovarian cancer,” Oncotarget , vol. 7, no. 11, pp. 12598–12611, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Zhou, H. Zhao, Z. Wang et al., “Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma,” Journal of Experimental & Clinical Cancer Research, vol. 34, no. 102, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Zhou, M. Guo, D. He et al., “A potential signature of eight long non-coding RNAs predicts survival in patients with non-small cell lung cancer,” Journal of Translational Medicine, vol. 13, no. 1, article no. 231, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Zhang, Z. Chen, X. Wang et al., “Long non-coding RNA: a new player in cancer,” Journal of hematology oncology, vol. 6, no. 37, 2013. View at Google Scholar
  21. N. Hauptman and D. Glavač, “Long non-coding RNA in cancer,” International Journal of Molecular Sciences, vol. 14, no. 3, pp. 4655–4669, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Chen, Z. Wang, D. Wang et al., “LncRNADisease: a database for long-non-coding RNA-associated diseases,” Nucleic Acids Research, vol. 41, no. 1, pp. D983–D986, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Liu, L. Wan, K. Lu et al., “The long noncoding RNA MEG3 contributes to cisplatin resistance of human lung adenocarcinoma,” PLoS ONE, vol. 10, no. 5, Article ID e0114586, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. X.-W. Zhang, P. Bu, L. Liu, X.-Z. Zhang, and J. Li, “Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance,” Biochemical and Biophysical Research Communications, vol. 462, no. 3, pp. 227–232, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. Q. Hang, R. Sun, C. Jiang, and Y. Li, “Notch 1 promotes cisplatin-resistant gastric cancer formation by upregulating lncRNA AK022798 expression,” Anti-Cancer Drugs, vol. 26, no. 6, pp. 632–640, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Fan, B. Shen, M. Tan et al., “Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling,” FEBS Journal, vol. 281, no. 7, pp. 1750–1758, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. Z. Liu, M. Sun, K. Lu et al., “The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21WAF1/CIP1 expression,” PLoS ONE, vol. 8, no. 10, Article ID e77293, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Yang, H. Li, S. Hou, B. Hu, J. Liu, and J. Wang, “The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell,” PLoS ONE, vol. 8, no. 5, Article ID e65309, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. Q. Wang, N. Cheng, X. Li et al., “Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma,” Oncotarget , vol. 8, no. 2, pp. 2558–2567, 2017. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Shi, J. Pu, X. Zhou, Y. Ning, and C. Bai, “Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway,” Tumour biology: The Journal of The International Society for Oncodevelopmental Biology and Medicine, vol. 39, article 1010428317697568, no. 5, p. 101042831769756, 2017. View at Publisher · View at Google Scholar
  31. G. Xu, J. Chen, and Q. Pan, “Long noncoding RNA expression profiles of lung adenocarcinoma ascertained by microarray analysis,” PLoS ONE, vol. 9, no. 8, Article ID e104044, 2014. View at Publisher · View at Google Scholar
  32. S. Ren, Z. Peng, J. Mao et al., “RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings,” Cell Research, vol. 22, no. 5, pp. 806–821, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. T. R. Mercer, M. E. Dinger, and J. S. Mattick, “Long non-coding RNAs: insights into functions,” Nature Reviews Genetics, vol. 10, no. 3, pp. 155–159, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. K. C. Wang and H. Y. Chang, “Molecular mechanisms of long noncoding RNAs,” Molecular Cell, vol. 43, no. 6, pp. 904–914, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. A. N. Khachane and P. M. Harrison, “Mining mammalian transcript data for functional long non-coding RNAs,” PLoS ONE, vol. 5, no. 4, Article ID e10316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. R. A. Gupta, N. Shah, K. C. Wang et al., “Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis,” Nature, vol. 464, no. 7291, pp. 1071–1076, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. X. Chen, “Predicting lncRNA-disease associations and constructing lncRNA functional similarity network based on the information of miRNA,” Scientific Reports, vol. 5, Article ID 13186, 2015. View at Publisher · View at Google Scholar
  38. X. Chen and G.-Y. Yan, “Novel human lncRNA-disease association inference based on lncRNA expression profiles,” Bioinformatics, vol. 29, no. 20, pp. 2617–2624, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. J. S. Mattick and M. J. Gagen, “The evolution of controlled multitasked gene networks: The role of introns and other noncoding RNAs in the development of complex organisms,” Molecular Biology and Evolution, vol. 18, no. 9, pp. 1611–1630, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. U. A. Ørom, T. Derrien, M. Beringer et al., “Long noncoding RNAs with enhancer-like function in human cells,” Cell, vol. 143, no. 1, pp. 46–58, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. J. S. Mattick, “Linc-ing long noncoding RNAs and enhancer function,” Developmental Cell, vol. 19, no. 4, pp. 485-486, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. M. A. Yemul, “A flail anterior tricuspid leaflet secondary to anteroposterior papillary muscle rupture in a neonate,” Journal of Echocardiography, vol. 31, no. 5, pp. E151–E155, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Pan, X. Li, W. Wu et al., “Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells,” Cancer Letters, vol. 382, no. 1, pp. 64–76, 2016. View at Publisher · View at Google Scholar · View at Scopus